Lexicon neurology, autoimmune, functional genomics news

Lexicon will restructure and reduce headcount by about 100 (18%) to 460 across the company. Lexicon said the move enables it to continue to invest in expanding its pipeline while maintaining a drug discovery operation. Lexicon’s lead compound is LX6171, a membrane protein inhibitor that is in Phase II testing to treat cognitive impairment. Lexicon out-licensed LX6171 and two other compounds to Symphony Icon Inc. (Rockville, Md.), which was formed by Symphony Capital Partners L.P. (see BioCentury, June 25, 2007). ...